Advertisement

The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol

      Abstract

      Background

      This clinical trial was conducted to demonstrate the efficacy and safety of a 91-day extended-regimen, low-dose combination oral contraceptive (OC) consisting of 84 days of ethinyl estradiol (EE) 20 mcg/levonorgestrel (LNG) 100 mcg, followed by 7 days of 10 mcg EE in place of placebo.

      Study Design

      A multicenter open-label, single-treatment, Phase 3 study evaluated women aged 18 through 40 years over a treatment period of up to 1 year (four 91-day extended cycles). All subjects completed daily paper diaries to monitor compliance, bleeding and additional forms of contraception used during the course of the study.

      Results

      A total of 1249 subjects completed the study. The Pearl Index was 2.74 (95% confidence interval, 1.92���3.78), based on 36 pregnancies that occurred after the onset of treatment and within 14 days after the last combination tablet in women aged 18���35 years. Among compliant-use subjects 18���35 years old, the Pearl Index was 1.73 based on 22 on-treatment pregnancies. The life table pregnancy rate for subjects 18���35 years of age was 2.39%. Cycle control and adverse events reported with this regimen were similar to those reported with other low-dose OCs.

      Conclusions

      This study demonstrated effective prevention of pregnancy with a 20-mcg EE, 91-day extended-regimen OC. In addition, the regimen was well tolerated and incidence of adverse events were consistent with what has been reported with other low-dose OCs.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gerstman B.B.
        • Gross T.P.
        • Kennedy D.L.
        • Bennett R.C.
        • Tomita D.K.
        • Stadel B.V.
        Trends in the content and use of oral contraceptives in the United States, 1964���88.
        Am J Public Health. 1991; 81: 90-96
        • Speroff L.
        • DeCherney A.
        Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins.
        Obstet Gynecol. 1993; 81: 1034-1047
        • Spitzer W.O.
        • Lewis M.A.
        • Heinemann L.A.
        • Thorogood M.
        • MacRae K.D.
        Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
        BMJ. 1996; 312: 83-88
        • WHO Collaborative Study of Cardiovascular Diseases and Steroid Hormone Contraception
        Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.
        Lancet. 1995; 346: 1575-1582
        • Gallo M.F.
        • Nanda K.
        • Grimes D.A.
        • Schulz K.F.
        Twenty micrograms vs. >20 mcg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials.
        Contraception. 2005; 71: 162-169
        • Fauser B.C.J.M.
        • van Heusden A.
        Manipulation of human ovarian function: physiological concepts and clinical consequences.
        Endocr Rev. 1997; 18: 71-106
        • Killick S.R.
        • Fitzgerald C.
        • Davis A.
        Ovarian activity in women taking an oral contraceptive containing 20 mcg ethinyl estradiol and 150 mcg desogestrel: effects of low estrogen doses during the hormone-free interval.
        Am J Obstet Gynecol. 1998; 179: S18-S24
        • Spona J.
        • Feichtinger W.
        • Kindermann C.
        • Wunsch C.
        • Brill K.
        Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol.
        Contraception. 1996; 54: 299-304
        • Schlaff W.D.
        • Lynch A.M.
        • Hughes H.D.
        • Cedars M.I.
        • Smith D.L.
        Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression.
        Am J Obstet Gynecol. 2004; 190: 943-951
        • Endrikat J.
        • Gerlinger C.
        • Plettig K.
        • et al.
        A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use.
        Gynecol Endocrinol. 2003; 17: 107-114
        • Reape K.Z.
        • DiLiberti C.E.
        • Hendy C.H.
        • Volpe E.J.
        Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive.
        Contraception. 2008; 77: 34-39
        • Vandever M.A.
        • Kuehl T.J.
        • Sulak P.J.
        • et al.
        Evaluation of pituitary���ovarian axis suppression with three oral contraceptive regimens.
        Contraception. 2008; 77: 162-170
        • Klipping C.
        • Duijkers I.
        • Trummer D.
        • Marr J.
        Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
        Contraception. 2008; 78: 16-25
        • Bachmann G.
        • Sulak P.J.
        • Sampson-Landers C.
        • Benda N.
        • Marr J.
        Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
        Contraception. 2004; 70: 191-198
        • Nakajima S.T.
        • Archer D.F.
        • Ellman H.
        Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 microg (Loestrin 24 Fe).
        Contraception. 2007; 75: 16-22
        • Archer D.F.
        • Jensen J.T.
        • Johnson J.V.
        • Borisute H.
        • Grubb G.S.
        • Constantine G.D.
        Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results.
        Contraception. 2006; 74: 439-445
        • Ortho Tri Cyclen�� Lo
        Current US Prescribing Information.
        Ortho-McNeil Pharmaceuticals, Inc., New Jersey2004
        • FDA Advisory Committee for Reproductive Health Drugs
        Final summary minutes. January 23���24, 2007.
        (Accessed March 20, 2009)
        • Holt V.L.
        • Scholes D.
        • Wicklund K.G.
        • Cushing-Haugen K.L.
        • Daling J.R.
        Body mass index, weight, and oral contraceptive failure risk.
        Obstet Gynecol. 2005; 105: 46-52
        • Holt V.L.
        • Cushing-Haugen K.L.
        • Daling J.R.
        Body weight and risk of oral contraceptive failure.
        Obstet Gynecol. 2002; 99: 820-827
        • Brunner L.R.
        • Hogue C.J.
        The role of body weight in oral contraceptive failure: results from the 1995 National Survey of Family Growth.
        Ann Epidemiol. 2005; 15: 492-499
        • Brunner Huber L.R.
        • Toth J.L.
        Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth.
        Am J of Epidemiol. 2007; 166: 1306-1311
        • Brunner Huber L.R.
        • Hogue C.J.
        • Stein A.D.
        • Drews C.
        • Zieman M.
        Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina.
        Ann Epidemiol. 2006; 16: 637-643
        • LaGuardia K.D.
        • Shangold G.
        • Fisher A.
        • Friedman A.
        • Kafrissen M.
        Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol.
        Contraception. 2003; 67: 431-437
        • Anderson F.D.
        • Feldman R.
        • Reape K.Z.
        Endometrial effects of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo.
        Contraception. 2008; 77: 91-96